Literature DB >> 10521199

Fortnightly review. Treatment of schizophrenia.

J McGrath1, W B Emmerson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10521199      PMCID： PMC1116843          DOI： 10.1136/bmj.319.7216.1045

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  14 in total

Review 1.  Treatment of schizophrenia.

Authors:  J M Kane; T H McGlashan
Journal:  Lancet       Date:  1995-09-23       Impact factor: 79.321

Review 2.  A new algorithm for treating schizophrenia.

Authors:  R Pearsall; I D Glick; D Pickar; T Suppes; J Tauscher; K O Jobson
Journal:  Psychopharmacol Bull       Date:  1998

Review 3.  The current status of neuroleptic therapy.

Authors:  J M Kane
Journal:  J Clin Psychiatry       Date:  1989-09       Impact factor: 4.384

Review 4.  Neuroleptics and the natural course of schizophrenia.

Authors:  R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

5.  Clinical use of high-dose neuroleptics.

Authors:  S R Hirsch; T R Barnes
Journal:  Br J Psychiatry       Date:  1994-01       Impact factor: 9.319

6.  Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

Authors:  M F Green; B D Marshall; W C Wirshing; D Ames; S R Marder; S McGurk; R S Kern; J Mintz
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

7.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

Authors:  A F Lehman; D M Steinwachs
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

8.  Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

Authors:  C Hagger; P Buckley; J T Kenny; L Friedman; D Ubogy; H Y Meltzer
Journal:  Biol Psychiatry       Date:  1993-11-15       Impact factor: 13.382

9.  Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.

Authors:  S Leucht; G Pitschel-Walz; D Abraham; W Kissling
Journal:  Schizophr Res       Date:  1999-01-04       Impact factor: 4.939

10.  Duration of psychosis and outcome in first-episode schizophrenia.

Authors:  A D Loebel; J A Lieberman; J M Alvir; D I Mayerhoff; S H Geisler; S R Szymanski
Journal:  Am J Psychiatry       Date:  1992-09       Impact factor: 18.112
View more
  7 in total

1.  Treatment of schizophrenia. Value of diagnosis of schizophrenia remains in dispute.

Authors:  P Bracken; P Thomas
Journal:  BMJ       Date:  2000-03-18

2.  Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease.

Authors:  Alan L Berkowitz
Journal:  Psychiatry (Edgmont)       Date:  2006-11

3.  Telling patients with schizophrenia their diagnosis. Patients should be informed about their illness.

Authors:  R A Clafferty; E McCabe; K W Brown
Journal:  BMJ       Date:  2000-08-05

Review 4.  Substance misuse in patients with schizophrenia: epidemiology and management.

Authors:  David J Kavanagh; John McGrath; John B Saunders; Glenys Dore; Dianne Clark
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  A mentally retarded patient with schizophrenia.

Authors:  K Rabia; Em Khoo
Journal:  Malays Fam Physician       Date:  2008-12-31

6.  Clozapine-induced interstitial nephritis - a rare but important complication: a case report.

Authors:  Robert Hunter; Tracey Gaughan; Filippo Queirazza; Dina McMillan; Susan Shankie
Journal:  J Med Case Rep       Date:  2009-08-27

7.  Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Authors:  Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.